MD, PhD student
After finishing his first two years of medical school, Henry joined the Gambello lab and contributed significantly to a publication on rapamycin treatment of mice with a conditional Tsc2 deletion in the brain. In addition, he spearheaded projects to characterize the metabolic phenotype of the Tsc2 conditional deletion mice. This led to his next research project in the Taegtmeyer lab on the role mammalian target of rapamycin (mTOR) plays in energy metabolism in the heart. Henry is currently in the Cuhna lab exploring the role of ankyrin-B in maintenance of cardiac rhythm.